Skip to content

Biz News Today

Business News – Direct Source News

  • Home
  • Business News Videos
    • International/National News Videos
  • Directory
  • Links PRs
  • REITS
  • About
  • Contact
    • Sitemap

Opdivo (nivolumab) Demonstrated Superior Disease-Free Survival in Patients with Resected Esophageal or Gastroesophageal Junction Cancer Compared to Placebo in the Adjuvant Setting

  • Home
  • 2020
  • September
  • 21
  • Opdivo (nivolumab) Demonstrated Superior Disease-Free Survival in Patients with Resected Esophageal or Gastroesophageal Junction Cancer Compared to Placebo in the Adjuvant Setting

Original Source

On September 21, 2020

Post navigation

Previous PostOpdivo (nivolumab) Plus Chemotherapy Demonstrated Significant Overall and Progression-Free Survival Benefits Versus Chemotherapy in First-Line Treatment of Gastric and Esophageal Cancers
Next PostBristol Myers Squibb Completes Acquisition of Forbius

Related Post

May 26, 2022
  • Business News

Examining the Effectiveness of Indexing Small Caps

May 25, 2022
  • Business News

Boeing, NASA Complete First Starliner Space Station Flight Test

May 25, 2022
  • Business News

Northrop Grumman Australia Announces Tech Showcase Winners

Copyright © All right reserved
Newslist Created By Rise Themes

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5219